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Summary. Hepatocyte growth factor (HGF), otherwise 
known as scatter factor (SF), has been demonstrated over 
the past decade to elicit a number of functions that may 
be tumorigenic, and enhance the invasive/metastatic 
nature of cancer cells. Clinical studies have also 
demonstrated that HGFJSF, together with its receptor, 
cMET, is closely related to the disease progression and 
prognosis of patients with cancer. The past few years 
have seen the identification of numerous inhibitors and 
antagonists to the action of HGFISF. These factors have 
demonstrated a possible role in minimising the action of 
HGFISF on cancer cells, and may be of therapeutic value 
in the future. This article overviews the activators, 
inhibitors, and antagonists to HGFISF and discusses the 
possible implications in cancer therapy. 
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lntroduction 
Since the discovery of HGFISF (hepatocyte growth 
factorlscatter factor) in the eighties, there has been 
vigorous interest to determine its roles in cancer 
development and cancer metastasis. HGFISF, via its 
action on its specific receptor, cMET, displays an array 
of biological functions in cancer cells, such as the 
enhancement of cell migration, invasion and matrix 
degradation, and induction of angiogesis. Its role in 
cancer development and progression has also been 
confirmed in clinical studies, where the leve1 of HGFISF 
and its receptor are associated with the disease 
progression and prognosis in patients bearing cancer. 
Recent efforts have also led to the discovery of a few 
agentslfactors that act as inhibitors to the action of 
HGFISF in cancer cells. This article will first briefly 
examine the action of HGFISF on cancer cells and go on 
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to discuss the activators and potential inhibitors for 
HGFISF. 
HGFISF elicits wide spectrum of effects on cancer 
cells and plays an important role in cancer 
progression 
The discovery of HGFISF indicated its importance 
on hepatocyte and epithelial cel ls .  Subsequent 
developments and identification of the HGFISF receptor 
has strongly indicated a role for HGFISF and its receptor 
in cancer and cancer progression (Fig. 1)  (Jiang and 
Hiscox, 1997a; Jiang et al., 1999a,b). 
HGF/SF affects tumour cell proliferation, growth, and cell 
cycle regulation 
Although the initial interest in HGFISF was on cell 
growth in hepatocytes, it was soon realised that HGFISF 
also governed the behaviour of cells other than that of 
liver cells. The factor has been shown to enhance the 
growth of a number of cancer cell types, including 
ovarian cancer cells (Corps et al., 1997), endometrial 
epithelial cells (Sugawara et al., 1997), neonatal 
hepatocytes (Pagan e t  al. ,  1997), hematopoietic 
progenitor cells (Weimar et al., 1995), gastric cancer 
cells (Kaji et al., 1996), renal cell carcinoma cells 
(Kobayashi et al., 1994), pancreatic cancer cells 
(Direnzo et al., 1995; Hasegawa et al., 1995) and 
prostate cancer cells (Humphrey et al., 1995). HGFISF 
regulated growth of cells appears to depend upon the 
type of tumour cells, as it exerts an inhibition of the 
growth of the melanoma cells, squamous cell carcinoma 
(SCC) cells, hepatocellular carcinoma (HCC) cells, and 
colon cancer cells (Tajima et al., 1991; Jiang et al., 
1993a). HGFISF has been reported to induced apoptosis 
in ovarian epithelial cells (Gulati and Peluso, 1997) and 
regulate cell cycle progression in tumour cells (Liu et al., 
1997). 
HGF/SF and cancer invasive/metastatic behaviour 
The presence of metastatic disease in cancer patients 
HGF/SF inhibitors in cancer 
is the most significant factor affecting their survival 
(Stracke and Liotta, 1995). HGFISF has been shown to 
affect a number of events in the metastatic process (Fig. 
1)- 
1. HGF/SF inhibits the assembly of adherens junctions 
Pasdar et al. (1997) showed that HGFISF treated 
cells failed to form stable cell-cell adhesion junctions 
due to an increased stability of the newly synthesized 
soluble E-cadherin and an altered phosphorylation 
pattern of E-cadherin within the cell. HGFISF has the 
ability to dissociate epithelial colonies and thus its 
effects on cellular adhesion molecules such as the 
cadherins has been studied. Cadherin function is 
modulated by intracellular proteins, temed catenins, that 
act as molecular linkers between the cytoplasmic domain 
of the cadherin protein and the cytoskeletal network 
within the cell (Jiang, 1996; Jiang et al., 1996a-c). 
2. HGF/SF may promote the dismantling of cell-cell 
adhesion complexes 
It has been postulated that HGFISF may inhibit 
cadherin function by altering the phosphorylation of 
these cadherin-associated proteins thus affecting their 
binding to the intracellular portion of E-cadherin. Hiscox 
and Jiang (1998) have reported that HGFISF enhances 
the tyrosine phosphorylation status of B-catenin and also 
results in the dissociation of B-catenin from E-cadherin. 
HGFISF-induced tyrosine phosphorylation of B-catenin, 
which may down-regulate cadherin-mediated cell-cell 
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adhesion by such a mechanism, has also been observed 
by others (Shibamoto et al., 1994; Tannapfel et al., 1994; 
Hiscox and Jiang, 1998). B-catenin also plays a central 
regulatory role in cell-cell adhesion and cell growth 
(Jiang and Hiscox, 1997b). 
3. HGF/SF and cell-matrix adhesion 
HGF/SF regulates matrix related parameters in 
cancer cells. The factor increases the adhesion of c-met 
positive B-lymphoma cells to fibronectin and also 
promotes their migration and invasion (Weimar et al., 
1997). Since these interactions are mediated via B1, 
a4B1 and a5B1-integrins, it is possible that HGFISF 
enhances the expression of such molecules on the cell 
surface. Evidence has shown that HGFISF does indeed 
alter the integrin expression pattern on several cell types, 
increasing the expression of a2Blon HepG2 liver cancer 
cells with a subsequent increase in the adhesive 
capabilities of these tumour cells toward both matrix and 
endothelial cells (Kawakamikimura et al., 1997). 
HGFISF has also been shown to affect the initial 
recruiting of integrins, cytoskeletal proteins, pp125FAK 
and paxillin into foca1 adhesion complexes via the 
tyrosine kinase activity of c-met (Matsumoto et al., 
1994; Jiang, 1996; Jiang et al., 1996a-c). Thus HGFISF 
affects both cell-matrix receptors (integrins) as well as 
intracellular post-receptor events. 
4. HGF/SF, matrix degradation and invasion 
HGFISF stimulates the invasion of tumour cells 
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through the matrix. The constitutively active met hybrid, 
TPRlc-met, is known to activate the uPA gene (Besser et 
al., 1997), to stimulate the production of tPA and uPA 
(Morimoto et al., 1994), to increase the expression and 
secretion of plasminogen activator inhibitor type 1 (PAI- 
1) and tissue factor in the human hepatoma cell line, Hep 
G2 (Wojta et al., 1994). HGFISF has also been shown to 
stimulate the production of matrix metalloproteinases 
(MMPs) by cancer cells (Bennett et al., 1997) and 
stimulate collagenase-1 and stromelysin-1 production in 
a dose-dependent and matrix dependent manner 
(Dunsmore et al., 1996). 
5. HGF/SF and tumour intra- and extravasation, 
endothelial interaction and homing 
HGFISF increases the adhesion of tumour cells to 
the endothelium by regulating a number of events 
involved in this interaction (Kawakamikimura, 1997). 
HGFISF increases the expression of CD44 on 
endothelial cells, a molecule which may play a critica1 
role in tumour-endothelial interaction and the 
establishment of metastasis (Hiscox and Jiang, 1997b). 
Furthermore, HGFISF also reduces the communication 
between the endothelial cells (Moorby et al., 1995; Jiang 
et al., 1997). 
6. HGF/SF and tumour cell motility 
HGFISF acts as a motility enhancer in a variety of 
cancer cells, including ovarian cancer cells (Corps et al., 
1997), colorectal cancer cells (Jiang et al., 1993b, 1996), 
breast cancer cells (Jiang et al., 1996b), melanoma cells 
(Jiang et al., 1993b) and lung cancer cells (Singhkaw et 
al., 1995; Harvey et al., 1996). 
7. HGF/SF and angiogenesis 
HGFISF is a known potent angiogenic factor and 
acts via the stimulation of endothelial cell proliferation 
and motility in vitro, altering the adhesive property of 
endothelial cells, to facilitate the formation of capillary 
tubules, and the migration of endothelial cells in the 
matrix (Fig. 1) (Bussolino et al., 1992; Comoglio et al., 
1993; Grant et al., 1993; Corps et al., 1997; Vanbelle et 
al., 1998). In vivo studies using HGFISF implants have 
revealed ingrowth of new blood vessels in mouse 
subcutaneous tissue and rat corneas (Rosen et al., 1990; 
Bussolino et al., 1992). Stimulation of human omentum 
mesentary endothelial (HOME) cells with HGFISF in 
the presence of active tissue plasminogen activator (tPA) 
results in the outgrowth of tubule-like structures, 
suggesting a co-operative role for these factors in 
eliciting angiogenic responses (Morimoto et al., 1994). 
HGF activator (HGFA) 
Discovery of HGFA 
HGFISF was discovered as a single chain protein, or 
pro-HGF. This form of HGFISF is inactive and unable to 
elicit any biological activities. This inactive single chain 
form of HGFISF, pro-HGFISF, requires site specific 
proteolytic cleavage, into the active heterodimeric form 
of HGFISF before it can elicit any biological action. 
Shimomura et al. (1992) reported the purification of 
a HGFISF-converting enzyme present in fetal bovine 
serum, by monitoring HGFISF conversion on SDS-page. 
Following this, the protein was purified from human 
serum. It was revealed that this serum protease was 
capable of converting pro-HGFISF into the active form 
of HGFISF in vitro, thus it was termed HGF Activator 
(HGFA) (Miyazawa et al., 1993). HGFA has since been 
shown to be the key mediator in the localised activation 
of HGFISF in injured tissue (Miyazawa et al., 1996). 
Biochemical characterisation and structure of HGFA 
The chromosomal location of the HGFA gene has 
been determined as 4p16 (Miyazawa et al., 1998), and 
the complete sequence of the HGFA gene was found to 
cover about 7.5 kb of DNA, consisting of 14 exons 
separated by 14 introns. Initiation of transcription occurs 
at a site 75 bp upstream of the translational start codon, 
and the coding region is composed of multiple putative 
domains. The first translation product of HGFA is the 
HGFA precursor. 
Many serine proteases are generated from their 
precursors, via limited proteolysis, upon the initiation of 
blood coagulation. HGFA appears to follow this trend, as 
HGFA also exists as a precursor form in the plasma. The 
HGFA precursor is made up of a single polypeptide 
chain, consisting of 655 amino acids, has a molecular 
weight of around 96kDa, and has no HGFISF converting 
ability (Shimomura et al., 1993). The cDNA sequence 
for this novel serine protease revealed that the active 
form of HGFA is derived from the COOH-terminal 
region of a precursor protein, and is composed of 
multiple domains. 
Thrombin converts the HGFA precursor into the active 
form of HGFA 
The HGFA precursor is inactive in plasma and does 
not possess the ability to convert single chain HGFISF, 
as it requires activation to fulfill the function of HGFISF 
activator. A presence in human serum initiates the 
activation of the HGFA precursor, as human serum 
revealed a high degree of HGFISF converting activity. 
Shimomura et al. (1993), examined the ability of various 
serine proteases, from the blood coagulation and 
fibrinolysis mechanisms, to act as activators of the 
HGFA precursor. They identified thrombin as the most 
effective protease for cleavage of the precursor. This 
cleavage occurred, via limited proteolysis, at the bond 
between Arg407 and Ile408, in vitro. Thrombin 
therefore, links HGFA to the blood coagulation cascade, 
as upon initiation of blood coagulation, the serine 
protease thrombin is generated from its precursor, pro- 
thrombin. Once active, the HGFA protease then has the 
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ability to convert pro-HGFISF into the active form of 
HGFISF. It is by this method, that active HGFISF is 
generated in the injured tissues (Miyazawa et al., 1994). 
The bioactive HGFA molecule is created through 
activation of HGFA precursor molecule, resulting from 
the removal of the NH2-terminal end. Evidence suggests 
that the purpose of this discarded region may have been 
to aid in the binding of the precursor to negatively 
charged substances. This removed part of the precursor 
contains structural domains which appear to be involved 
in the interaction with anionic surfaces, and consists of 
type 1 and type 11 fibronectin domains, two EGF 
domains and a kringle domain. It has been shown in 
vitro that the inactive HGFA precursor can be effectively 
cleaved by thrombin, in the presence of negatively 
charged substances. This cleavage of the HGFA 
precursor results in the generation of severa1 fragments, 
although the 2 major fragments produced are 66kDa and 
34kDa in size. The 66kDa fragment represents the 
inactive NHZterminal region of the precursor which 
may have been involved in the binding of the precursor 
to the cell surface for activation by thrombin (Furie and 
Furie, 1988). Whereas, the 34kDa fragment represents 
the active form of HGFA and is composed of the COOH- 
terminal region. 
HGFA homologues 
It was obsewed that the amino acid sequences of the 
HGFA peptide domains revealed a high degree of 
similarity to the corresponding region of other serine 
proteases. These proteases included blood coagulation 
factor XII (Hageman Factor), tissue-type Plasminogen 
Activator (tPA) and Urokinase. These serine proteases 
have in the past been reported to convert pro-HGFISF 
into the active form of HGFISF in vitro (Naldini et al., 
1992; Mars et al., 1993). The degree of similarity 
between these factors and the HGFA precursor were as 
follows: Factor XII (47%), tPA (40%) and urokinase 
(38%) (Miyazawa et al., 1993). Factor XII is itself a 
precursor to the active serine protease Factor XIIa and 
shares a high degree of similarity to the HGFA 
precursor. His447, Asp497 and Ser598 are also present 
in the same corresponding position in each of the above 
serine proteases, and are present in the catalytic triad of 
the proteases and make up the active site. 
HGFISF has a very high sequence similarity to 
plasminogen, for this reason, the proteases that activated 
plasminogen were examined for their ability to activate 
HGFISF. Reports suggested that pro-HGFISF could be 
converted to HGFISF by the serine proteases that 
activate plasminogen, these serine proteases included 
urokinasé, tPA andpíasmin (Gak et d., 1992; Naldini et 
al., 1992). 
~ i z u n o  et al. (1992), however, reported confiicting 
results and showed that these enzymes did not induce 
any detectable leve1 of HGF converting ability. Mizuno 
et al. (1994), then went on to purify and characterise a 
new serine protease that did reveal HGFISF converting 
ability and designated it the HGF-converting enzyme. 
This enzyme is a disulphide-linked heterodimer with a 
molecular mass of about 90kDa, and is composed of a 
65kDa heavy chain and a 32kDa light chain. 
Serine proteases that share sequence similarities with 
HGFA (tPA, urokinase and Factor XIIa) had in the past 
been reported as possessing the ability to convert pro- 
HGF to the heterodimeric active form of HGFISF. 
However, Shimomura et al. (1995), also reports that t-PA 
and urokinase are not the major HGFISF converters, as 
the ability of urokinase and tPA to convert pro-HGF to 
active HGFfSF was over a 1000 times lower than that of 
HGFA and Factor XIIa. 
The full nucleotide sequence for the HGFA 
precursor shares 39% homology with the multiple 
putative domains of blood coagulation Factor XII. The 
bioactive Factor XIIa is also similar to HGFA in that it is 
first synthesised as an inactive precursor and requires 
activation to elicit any biological function. Factor XII is 
activated via proteolytic processing with plasma 
kallikrein to generate Factor XIIa, however, plasma 
kallikrein did not possess the ability to convert the 
HGFA precursor into the active form (Shimomura et al., 
1992). There is substantial similarity between the 
structural formations of HGFA and factor XIIa, as factor 
XII is composed of al1 the same structures as the HGFA 
precursor, plus has similar exonlintron arrangements. 
This could suggest that both HGFA and Factor XII genes 
could have originally been from the same ancestoral 
gene, but are now different due to evolutionary 
divergence. 
Recently, a novel plasma hyaluronan-binding protein 
(PHBP) was purified from human plasma, the amino 
acid sequence of which revealled significant homology 
to HGFA (31%) (Choi-Miura et al., 1996). The structural 
differences between HGFA and PHBP are that the 
HGFA precursor is composed of a characteristic 
structural domain, type 1 and 11 fibronectin domains, two 
EGF domains, a kringle domain and a serine protease 
domain, whereas, PHBP consists of 3 EGF domains, a 
kringle domain and a serine protease domain. Also, 
PHBP is located on chromosome 10 (Sumiya et al., 
1997), unlike HGFA, which is located on chromosome 4. 
The gene for PHBP also revealed significant similarity to 
FXII, tPA and urokinase, for these reasons PHBP may 
play a role in activation of HGFISF or plasminogen. 
The multiple functions of HGFA 
The leading contenders for the major protease for 
HGFISF conversion were HGFA, the HGFISF 
converting enzyme and Factor XIIa. Human serum 
normally possesses a high pro-HGFISF-converting 
ability. This serum was analysed in the presence of a 
monoclonal antibody (Pl-4) known to inhibit the action 
of HGFA. The results revealed that the ability of human 
serum to convert pro-HGF into the active form was 
almost completely lost. Therefore, neither the HGF- 
converting enzyme nor Factor XIIa are the major pro- 
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HGFJSF activators in human serum, as Shimomura et al. 
(1995), demonstrated that HGFA is the main protease 
responsible. 
Prothrombin is activated to create the mature form of 
thrombin which plays a central role in blood 
coagulation. Thombin is  also responsible for the 
activation of the HGFA precursor (Shimomura et al., 
1993), thereby linking the HGFA precursor activation to 
the blood coagulation cascade. Factor XIIa, which shares 
significant homology to HGFA, is  the protease 
responsible for the initiation of the blood coagulation 
cascade. Reports suggest the conversion of the inactive 
HGFA precursor to the active form of HGFA is initiated 
in response to blood clotting following tissue injury. 
Once the HGFA protease is active it can convert pro- 
HGF to the active heterodimeric form of HGFISF, 
thereby activating a multi-functional cytokine that 
facilitates tissue regeneration. 
Once activated, HGFA also has the ability to interact 
with heparin, which may serve to aid the localisation of 
HGFISF cleavage, and linking activation to blood 
coagulation. Proteolytic activation of HGFISF occurs in 
the injured tissues, thus it seems evident that the 
activation system for HGF/SF can be regulated locally 
(Miyazawa et al., 1994). 
Okajima et al. (1997), suggests that HGFA is an 
acute phase protein of the acute inflammatory response, 
as the HGFA mRNA level increases, following tissue 
injury resulting in acute inflammation. The precise role 
of HGFA in relation to the inflammatory response is 
unclear. 
HGFA may also play a role in the conversion of pro- 
HGF to HGFJSF during the process of mammalian 
development, as HGFJSF has been shown to be a 
necessity for mouse development (Uehara et al., 1995). 
HGFA is responsible for HGF/SF activation 
During tissue damage, HGFJSF activation functions 
as a mechanism for localising the biological functions 
and role of HGFJSF in tissue regeneration. Furthermore, 
in cancer states, HGFJSF activation is thought to be a 
method of aiding tumour progression. Enzymatic 
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Fig. 2. Activation of HGFISF. Pro-HGFISF is activated by HGF activator 
(HGFA), which itself is activated by other proteases. 
activity, with the ability to convert pro-HGFISF to 
HGFISF, was obsewed in the injured liver. Other studies 
report that the level of active HGFISF increased in the 
liver and kidney upon treatment with hepatoxin and 
nephrotoxin, respectively (Fig. 2). 
HGFISF in its normal state can be found as the 
inactive precursor form of pro-HGFISF. For HGFISF to 
evoke its biological function as a mitogen, motogen and 
morphogen, it first has to be converted from the inactive 
single chain form of pro-HGFISF to the heterodimeric 
form of active HGFISF. Pro-HGF requires activation as 
it has no biological effect on its own. Aithough, at one 
stage pro-HGFISF was  considered to possess a 
mitogenic ability on cultivated hepatocytes, but in the 
presence of leupeptin, an inhibitor for any protease 
activation of pro-HGF, this mitogenic function was lost 
(Mizuno et al., 1992). 
Pro-HGFJSF is synthesised as a 728 amino acid 
precursor (Nakamura et al., 1989),  then cleaved 
intracellularly through removal of the NH2-terminal end 
(31 amino acid residues) as a signal peptide (Yoshiyama 
et al., 1991). Pro-HGFJSF is secreted in this precursor 
form and undergoes proteolytic processing in human 
serum. 
It has been shown that for HGFISF to elicit its 
biological effects, it requires proteolytic activation from 
the single chain pro-form (Fig. 2) (Gak et al., 1992; 
Hartmann et al., 1992). This conversion requires site 
specific extracellular hydrolysis of the Arg494-Va1495 
peptide bond to yield a heavy of 69 kDa chain (a-chain), 
and a light chain of 34 kDa (B-chain), which are joined 
together by a disulfide bond. The B-subunit of the 
HGFJSF molecule contains a serine protease-like 
domain, although it has no protease activity because it 
lacks the presence of triad residues at the active site, 
which are conserved in the active serine proteases 
(Nakamura et al., 1989). 
The HGF-converting enzyme was described by 
Mizuno et al. (1994), as a serine protease with the ability 
to convert pro-HGFISF to HGFISF in vitro. Also, it was 
previously reported that the enzymes tissue-type 
plasminogen activator (t-PA), urokinase and plasmin al1 
possessed the ability to convert pro-HGFISF into its 
active form. Previously these enzymes had been shown 
to possess the abilty to convert plasminogen, a sequence 
with high homology to HGFISF, into its active form. 
However, it was later reported that these enzymes do not 
cleave pro-HGFISF into HGFISF (Mizuno et al., 1992). 
Conflicting data suggested that urokinase did have the 
ability to convert pro-HGFISF in vitro, although the 
reaction was slow (Naldini et al., 1992, 1995). 
Eventually, it was discovered that HGFA was the 
main HGFJSF activator, and that this serine protease was 
a 1000-fold more efficient at HGFJSF activation than 
urokinase and t-PA (Shimomura et al., 1995; Miyazawa 
et al., 1996). 
HGFA was also shown to have a greater ability to 
activate HGFISF, than Factor XIIa, and was therefore 
confirmed as the main protease for HGFISF activation in 
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serum (Shimomura et al., 1995). HGFA acts as a typical 
catalyst, activating pro-HGFISF quantitatively. The 
protease itself is a precusor present in the blood, and 
only found in its active state in the serum. This activation 
by HGFA takes place in the extracellular enviroment and 
is the limiting step in the HGF signalling pathway. 
Reports also suggested that, locally synthesised, HGFA 
plays a role as a regulator of the morphogenic action of 
HGFISF on gastrointestinal tract development in the 
fetal rat (Matsubara et al., 1998). 
HGFA is activated by thrombin, and during blood 
coagulation thrombin is produced, therefore activation of 
the HGFA precursor increases due to blood coagulation 
resulting fiom tissue injury. This would suggest HGFA is 
activated in response to tissue damage (Miyazawa et al., 
1994). 
The mature HGFA has a strong affinity for heparin, 
as does the inactive HGFISF. Pro-HGFISF is capable of 
binding to cell surfaces or the extracellular matrix to for 
activation, this binding is enhanced by its affinity to 
heparin-like glycosaminoglycans (Naldini et al., 1991). 
Therefore, linking the localised HGFISF activation to 
blood coagulation and the need for active HGFISF 
following tissue damage (Miyazawa et al., 1996). 
This ties in with the ability for active HGFA to 
convert pro-HGFISF on the cell membrane, as once the 
HGFA protease is mature it is aquires the ability to 
interact with heparin (Miyazawa et al., 1996), thereby 
ensuring local activation of pro-HGFISF by HGFA. 
Also, Moriyama et al., (1995), report the joint expression 
of HGFISF, HGFA and the HGFISF receptor (c-met) in 
glioma cells, suggesting a self regulatory mechanism. 
Therefore, it appears the HGFISF is activated on the cell 
surface or extracellular matrix of the tissue, that requires 
regeneration, at the site of tissue damage. 
HGFA and thrombin are the proteases responsible 
for HGFISF and HGFA activation, respectivly. For this 
reason, it appears that following tissue damage, the 
inflammatory response and the blood coagulation 
cascade are initiated and produce thrombin. This 
thrombin then converts the secreted HGFA precursor 
into active HGFA, in the serum and at the site of the 
tissue injury. Once active, HGFA has the ability to 
induce the localised conversion of pro-HGFISF to 
HGFISF at the site of the damage, the active form of 
HGFISF then plays its role in the tissue regeneration 
process. This process of events would explain how the 
active form of HGFISF was cleaved exclusively in 
injured tissues. 
Controlling the activation of HGFA may act as a 
means of mediating the biological influence of HGFISF, 
therefore, serine protease inhibitors were employed to 
examine possible methods of decreasing HGFA activity. 
Serine protease inhibitors, naturally present in human 
serum, include antithrombin 111, c-1 inhibitor and a2- 
antiplasmin and are capable of inhibiting the blood 
clotting ability of Factor XIIa (Tans and Rosing, 1987). 
The HGFISF converting ability of Factor XIIa and 
HGFA was examined in the presence of these protease 
inhibitors. The inhibitors suppressed the influence of 
Factor XIIa, but none of these inhibitors could prevent 
HGFA converting pro-HGFISF to HGFISF (Shimomura 
et al., 1995). However, the HGFISF converting ability 
observed in injured tissues was inhibited, in vitro, by an 
anti HGFA antibody known as P1-4. Using this method, 
Miyazawa et al. (1996), confirmed HGFA as the 
mediator of HGFISF activation in injured tissues. One 
study reports that regulation of pro-thrombin secretion 
could play a role in mediating tissue regeneration as the 
active form, thrombin, cleaves the HGFA precursor to 
create the active form of HGFA (Yagi et al., 1995). 
During tissue injury there are two methods of 
regulation of HGFISF activity, 1 )  the localised 
proteolytic activation by HGFA; 2) enhanced production 
of HGFISF mRNA, via activation of HGFISF expression 
at the transcriptional level, therefore to understand the 
mechanism involved we need to know the factors 
involved in inducing gene transcription to completely 
understand the role HGFISF plays in tissue regeneration. 
The limiting step of the HGFISF signalling pathway 
in vivo, appears to be: 1) the extracellular activation of 
HGFISF by HGFA, 2) the inhibition of this protease by 
HAI-1 and HAI-2 (see later); 3) or maintaining the 
balance of the levels of active HGFA and HAI-112 to 
control HGFISF activation. 
HGFA expression and localisation 
Miyazawa et al., (1993), initially detected HGFA in 
the liver with northern blot analysis. Since then, the 
parenchymal cells of the rat liver have also been reported 
as a major site of HGFA mRNA synthesis, following 
tissue injury or acute inflammation (Okajima et al., 
1997). 
It was observed that no noteable mRNA signal for 
HGFA was detectable in colon carcinoma cell lines or in 
normal and malignant colonic mucosa (Kataoka et al., 
1998). However, Moriyama et al. (1995), reports the 
expression of the HGFA gene in human normal brain 
tissue and in glioma cells. Whereas, in situ hybridisation 
histochemistry was performed to reveal the presence of 
HGFA mRNA in white matter astrocytes of brain tissue 
(Yamada et al., 1997). 
It was reported that the active form of HGFA was 
generated exclusively in the injured tissues (Miyazawa et 
al., 1996). When injury was induced on the liver, 
HGFISF conversion occurred at this site but not at the 
kidney, lung or spleen. Whereas, when the rat was 
treated with nephrotoxin, the kidney was injured 
resulting in an increase in the presence of active HGFA 
to the level required for HGFISF conversion. Dunng this 
time, HGFISF conversion was not detected in the liver, 
lung or spleen. Another study reports that in normal 
gastric mucosa HGFA is not expressed, but following 
ulceration damage HGFA is expressed in the submucosa 
of the stomach (Kinoshita et al., 1997). 
Miyazawa et al. (1996), suggested that heparin may 
increase the ability of HGFA to activate HGFISF in the 
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site of the injury, due to the affinity of HGFA and 
HGFISF to heparin on the cell surface. The active form 
of HGFA is associated with the cell surface, as tissue 
injury requires that HGFA action is retained in the close 
vicinity of the injury. To localise HGFA action, this 
protease is able to bind to heparin-like molecules thereby 
associating with the cell surface and thus preventing free 
diffusion. This method of cell association ensures 
localised HGFA action and also a more efficient pro- 
HGFISF conversion as the pro-HGFISF molecule also 
binds to heparin-like molecules on the cell surface for 
activation (Naldini et al., 1992). 
The HGFA precursor itself does not have the ability 
to bind to heparin and is also diffusable, as it circulates 
in the plasma in this inactive form. Therefore this 
precursor appears to be secreted, then travels to a site 
requiring the influence of HGFISF, such as with tissue 
regeneration, whereupon it is activated to HGFA, by 
thrombin, ready for converting pro-HGFISF to HGFISF. 
This active HGFA is only present in the serum, and 
converts HGFISF following the secretion of pro-HGFISF 
into the extracellular enviroment (Mizuno et al., 1992). 
Patterns of HGFA expression 
In the fetal rat gastrointestinal tract, a pattern was 
obsewed between HGFA and the HGFISF receptor (c- 
met) mRNA expression. It was observed that HGFA 
mRNA was only present in epithelial cells expressing c- 
met mRNA (Matsubara et al., 1998). 
Rat HGFA mRNA expression, following liver injury, 
was shown to increase to as much as double during the 
first 6 hours following the initial injury, followed by a 
decrease over the following 24 hour period. The same 
increase in liver HGFA mRNA was obsewed following 
renal injury and also during acute inflammation 
(Okajima et al., 1997). This group also proposed that the 
increase in HGFA mRNA level was due to the tissue 
injury initiating the inflammatory response of which 
HGFA was reported as a possible acute phase protein. 
Following tissue injury, HGFA activity could possibly be 
enhanced due to increased HGFA mRNA production in 
the liver, via the inflammatory response, and increased 
activation of the HGFA precursor, via thrombin in the 
blood coagulation cascade. The cytokines IL-1 and IL-6 
are known to mediate the mRNA level of acute phase 
proteins during the inflammatory response. However, 
Okajima et al. (1997), revealled that neither IL-1 or IL-6 
had any effect on the HGFA mRNA level. 
lmplications in cancer 
The role of HGFISF in tumours is  stil l  not 
completely understood. It was the recognition of the 
HGFISF receptor as being c-met, discovered as an 
activated oncogene (Cooper et al., 1984), that increased 
the efforts to fully understand the role that HGFISF plays 
in cancer. Pro-HGFISF is secreted by mesenchyme cells 
and activated in the extracellular environment by HGFA. 
HGFA therefore plays a key role in the regulation of 
HGFISF-induced action during tumour progression. 
In Europe and North America, breast cancer is the 
second largest cause of cancer related death in women. 
HGFISF has been shown to enhance the metastatic 
potential of breast cancer cells in vitro. Studies have also 
revealed that the levels of HGFA are elevated in breast 
tumour tissue (Hiscox et al., 1998), which may result in 
increased conversion of pro-HGFISF to the 
heterodimeric active form of HGFISF, thereby 
promoting tumour metastasis. Also, it has been noted 
that increased expression of plasminogen activator, 
which shows significant homology to the HGFA 
precursor, in breast cancer cel ls  correlates  with 
tumorigenic progression (Spyratos et al., 1992). 
It was therefore important to discover if there was a 
mediator available for the production of HGFA, because 
cancer studies could then look at HGFA as a possible 
target of inhibition. If HGFA activity could be down- 
regulated then the influence of HGFISF on cancer cells 
could be suppressed. 
Recently, an inhibitor for HGFA was discovered 
(Shimomura et al., 1997), this inhibitor was identified as 
a novel kunitz-type serine protease inhibitor and termed 
HM. 
HGF activator inhibitors (HA/) 
As already discussed, HGFA was found as  an 
inactive precursor in human plasma, but was detected in 
its active form in human serum, this suggests that the 
factor responsible for inhibiting HGFA action is not 
present in the serum. Reports show that the action of 
HGFA is not inhibited by plasma proteinase inhibitors, 
because of the presence of the active form of HGFA in 
serum. Therefore, it seemed reasonable to assume that an 
inhibitor to HGFA could be produced in the tissues. 
Discovery of HA1 
Shimomura et al. (1997), examined human cell lines 
for an inhibitor to HGFA action and observed an 
inhibitory factor in the conditioned media of various cell 
lines. This protein was then purified from a human 
MKN45 stomach carcinoma cell line and cloned to 
reveal a novel Kunitz-type serine protease inhibitor. The 
newly discovered HGFA inhibitor was designated HGF 
activator inhibitor (HAI) (Shimomura et al., 1997). 
However, soon after the discovery of HAI, 
Kawaguchi et al. (1997), identified a second inhibitor of 
HGFA action from the conditioned media of the stomach 
carcinoma cell line MKN45. This newly discovered 
HGFA inhibitor was purifed, cloned and found to be 
another new Kunitz-type serine protease inhibitor. To 
distinguish between these two very similar HGFA 
inhibitors, HA1 was re-designated HAI-typel (HAI-1) 
for the initial discovery, and HAI-type 2 (HAI-2) for this 
newly identified HGFA inhibitor. 
HAI-1 and HAI-2 belong to a family of Kunitz-type 
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serine protease inhibitors. The initial discovery of a 
Kunitz-type serine protease inhibitor was upon the 
recognition of bovine pancreatic trypsin inhibitor 
(BPTI), also known as aprotinin (Laskowski and Kato, 
1980). 
HAI-1 is classed as a Kunitz-type serine protease 
inhibitor due to the similarity it shares with this family 
of inhibitors in the residue reigons 250-300 and 375-425, 
as  these regions contain the Kunitz domains. The  
primary HAI-1 translation product is made up of 513 
amino acid residues. HAI-1 is composed of an NH2- 
terminal putative signal peptide (1-35 residues), kunitz 
domain 1 (250-300 residues) and kunitz domain 2 (375- 
425 residues), each kunitz domain contains three 
disulphide bonds. The region between these kunitz 
domains (319-353 residues) shares a high similarity to 
the low density lipoprotein (LDL) receptors binding 
domain. There is also a hydrophobic region about 20 
amino acids at the COOH-terminal end (Shimomura et 
al., 1997). 
The NH2-terminal is 35 residues from a signal 
peptide, and there is a transmembrane domain in the c- 
terminal region (Yamada et al., 1998). 
The mature form of the HAI-1 molecule has a 
molecular mass of around 40 kDa. However, it was 
calculated that the expected molecular mass of the 
primary translated product of HAI-1 should be 56,893, 
but it is secreted as 40kDa, therefore this mature secreted 
form appears to be cleaved at the c-terminal region 
(Yamada et al., 1998). 
Recently, Shimomura et al. (1999), identified severa1 
new soluble forms of HAI-1. These soluble forms differ 
in form depending upon their site of cleavage, as the 
primary translation product contains multiple sites for 
proteolytic processing. 
HAI-2 has similar structural domains to HAI-1. The 
size of mature HAI-2 is smaller with a molecular mass 
of about 14kDa, although the primary translation product 
was expected to be 25,415Da. Therefore, as with HAI-1, 
the purified form of HAI-2 from the conditioned 
medium is the proteolytically truncated form of the 
membrane form. HAI-2 does not have the same length 
NH2-terminal, and there is no LDL ligand binding 
domain between the two kunitz domains (Kawaguchi et 
al., 1997). 
The primary translation product of of HAI-2 is 
composed of 252 amino acid residues. The NH2- 
terminal is composed of the putative signal peptide (1-27 
residues), kunitz domain 1 (38-88 residues), kunitz 
domain 2 (133-183 residues), and a hydrophobic region 
(198-221 residues) at the COOH-terminal end 
(Kawaguchi et al., 1997). 
Itoh et al. (1999), detected a new HAI-2 variant in 
mice. This HAI-2 variant was obtained from mouse 
kidney by RT-PCR, and it was revealled that this variant 
was shorter than HAI-2 because it lacked the first kunitz 
domain. However, they also reported that this form of 
HAI-2 was not present in human tissue. 
Roles of HA/-1 and HA/-2 structural domains 
The structures known as Kunitz domains, are also 
present in severa1 mammalian serine protease inhibitors, 
and appear to be responsible for the inhibitory action of 
the protein concerned. 
HAI-1, when proteolytically truncated into its 
extracellular active form, has a molecular mass of 
40kDa, this means that it consists of approximately 360 
amino acids. Due to HAI-1's original size of 513 amino 
acids and location of the structural domains, it would 
suggest that the cleavage occurs in the second kunitz 
domain to release the truncated form. This truncated 
form is composed of the NH2-terminal, the Kunitz 
domain 1, and the LDL receptor-like domain. On this 
evidence it could be proposed that Kunitz-domain 1 is 
the domain required to exert the inhibitive qualities of 
HAI-1 on the HGFA protease. 
Qin e t  al. (1998), proved this in HAI-2 with 
biochemical analysis by introducing point mutations into 
each of the kunitz domains, and monitoring their ability 
to inhibit HGFA activity. A point mutation in kunitz 
domain 2 had no effect on the HAI-2 proteins ability to 
inhibit HGFA action. However, a point mutation in 
kunitz domain 1 did suppress the ability of HAI-2 to 
inhibit HGFA. Therefore, it can be said that kunitz 
domain 1 (NH2-terminal end), is the kunitz domain 
responsible for inhibition of HGFA converting ability. 
As only the presence of Kunitz domain 1 is required 
for HGFA suppression, then maybe Kunitz domain 2 has 
an alternative responsibility. Kunitz domain 2 may act as 
an inhibitor for another serine protease, as reports 
suggest that HAI-2 is identical to the placental protein 
Bikunin (Qin et al., 1998). Also, Bikunin has also been 
reported a s  being a gene homolog to a protein 
overexpressed in pancreatic cancer known as KOP 
(Muller-Pillasch et al., 1998). Placental bikunin contains 
the kunitz domain 2, and it seems evident that this 
domain is responsible for inhibiting trypsin, tissue 
kallikrein, plasma kallikrein and plasmin (Delaria et al., 
1997). Therefore, this may suggest that HAI-2, Bikunin 
and KOP genes are from the same ancestoral gene, and 
that the role of Kunitz domain 2 is dependant upon the 
the protein inhibitor it is expressed in. It may act as an 
inhibitory factor for one serine protease but may not 
elicit any effect on another. 
The LDL receptor-like domain contains a negatively 
charged domain, the reason for which is unknown, 
although it may aid in formation of a protease inhibitor 
complex during the inhibition of HGFA by HAI-1 
because the HGFA precursor revealed high affinity for 
negatively charged substances. 
The presence of a hydrophobic sequence in the 
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COOH-terminal of the primary translation products, of 
both HAi-1 and HAi-2, suggests that they are produced 
in a membrane-associated form, and then proteolytically 
cleaved into a truncated form and secreted into the 
extracellular environment (Kawaguchi et al., 1997). 
However, the newly discovered soluble HAI-1 forms 
were identified in a transmembrane form integrated into 
the cells plasma membrane. These soluble HAI-1 forms 
vary in size depending on the site of proteolytic 
cleavage. The transmembrane associated form reveals 
multiple sites for proteolytic processing. There are at 
least two proteases, one of which is a metalloprotease, 
which can cleave at a specific site to release a soluble 
form of HAI-1 (Shimomura et al., 1999). 
Structural differences occur between HAI-1 and 
HAI-2, these include the different N-linked sugar chains 
that are joined to the protein portion, and also HAI-1 
was adsorbed by a hydrophobic column, whereas, HAI-2 
was not. This indicates that HAI-2 is more hydrophilic 
than HAI-1. 
Slight differences also occur in the Kunitz domains, 
as Kunitz domain 1 of HAI-1 and HAI-2 share 54% 
homology. However, the homology between the kunitz 
domain 1 and 2 of HAI-2 is only 41% (Qin et al., 1998). 
Símilarities of HA/- 1 and HA/-2 to other molecules 
Kunitz domains 1 and 2 in HAI-1 show 47% 
homology to kunitz domain 1 of the precursor of human 
O-amyloid (APP), and the kunitz domain 2 of the human 
APP homolog protein, respectively. APP effectively acts 
an inhibitor to severa1 serine proteases (Sinha et al., 
1990), however, APP shows no inhibitory action toward 
HGFA (Kawaguchi et al., 1997). 
Muller-Pillasch et al. (1998), discovered a novel 
putative transmembrane protein that was over expressed 
in pancreatic cancer, and designated it KOP (kunitz 
domain containing protein overexpressed in pancreatic 
cancer). This new protein is located on chromosome 
19q13.1, contains two kunitz-type serine protease 
inhibitors, and importantly was found to be a gene 
homolog to bikunin. Bikunin has previously been 
suggested as being identical to HAI-2, therefore it 
appears the KOP gene is also homologous to HAI-2. 
Comparison of the cDNA sequences of KOP, placental 
bikunin and HAI-2 has revealled that al1 3 proteins are 
identical (Qin et al., 1998). 
The roles played by HA/- 1 and HA/-2 
The inhibitory action of HAI-112 on HGFA could 
lead to consequences resulting from the suppression of 
HGFA action. Tissue repair requires the influence of 
HGFISF to initiate mitogenesis, therefore HGFA plays 
an important role as pro-HGFISF activator. HAI-112 
effectively suppress HGFA action to inhibit the 
requirements of HGFISF during tissue repair. 
Tumourigenesis is a multistep process which, to be 
understood, requires identification of al1 genes involved. 
For this reason, recognition of new proteases and 
protease inhibitors is an important step in understanding 
the mechanisms involved in cancer. A disruption of the 
balance between these proteases and their inhibitors has 
been reported to be a key factor in tumour progression 
(Declerk and Imren, 1994). 
lnhibition of HGFA by HA/- 1 and HA/-2 
It is evident that both HAI-1 and HAI-2 are the 
inhibitors responsible for the inhibition of the proteolytic 
activity of HGFA in vitro (Kawaguchi et al., 1997; 
Shimomura et al., 1997). Shimomura et al. (1997), 
revealed that 50% inhibition of the activity induced by 
450ng/ml of HGFA can be achieved with HAI-1 at a 
concentration of 250ng/ml. An equimolar complex is 
formed following 30 minutes incubation of HGFA with 
HAi-1. Whereas, it was reported that 300nglml of HAi-2 
was sufficient to induce a 50% inhibition of 2 pg/ml of 
HGFA (Kawaguchi et al., 1997). 
HAI-112 bind to the HGFA serine protease, to 
prevent it from binding to the single chain form of 
HGFISF and cleaving it into the active heterodimer of 
HGFISF. The inhibiting abilities of HAI-112 are reliant 
upon the presence of kunitz domain 1. However, it also 
appears that different forms of HAI-112 have differing 
inhibitory action against HGFA. 
HA/ expression 
The primary translational product of HAI-112 
suggests that these inhibitors are produced in a 
membrane associated form, due to the presence of a 
hydrophobic region in the COOH-terminal end of the 
sequence. To be secreted in the appropriate form, these 
products require cleavage at the c-terminal region. When 
HAI-1 and HAI-2 are secreted from the celís, they are in 
the proteolytically truncated form of 40 kDA and 14 
kDa, respectively. However, the new soluble forms of 
HAI-1 are released from a transmembrane associated 
form, via proteolytic processing of a specific cleavage 
site by a specific protease. 
HAi-112 expression in human liver was low, whereas 
with HGFA protease mRNA, the degree of expression in 
the liver was observed in high levels, as HGFA is 
secreted from liver (Kawaguchi et al., 1997). This shows 
that HAI-112 levels in the adult liver and lung are low, 
which is to be expected as HGFISF plays a key role in 
liver and lung tissue regeneration. Therefore, a high level 
of HGFA is required for the conversion of pro-HGFISF 
to HGFISF at this site. 
HAI-1 mRNA has been detected in high levels in 
adult placenta, pancreas, kidney, prostate and small 
intestine, furthermore, HAI-1 mRNA has also been 
observed in fetal kidney and lung. However, in adult 
lung the level of expression was low (Shimomura et al., 
1997). HAi-1 mRNA is expressed in colorectal mucosa1 
tissue (Kataoka et al., 1998), and on the surface of colon 
epithelial cells. 
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KOP, the similarlidentical gene to HAi-1 and HAI-2, 
was also seen to be highly expressed in placenta and 
pancreatic tissue, whereas low levels were detected in 
heart, lung, brain, liver, and skeletal muscle (Muller- 
Pillasch et al., 1998). However, HAI-1 mRNA was 
observed at a detectable level in the white matter of al1 
brain tissue astrocytes examined (Yamada et al., 1998). 
HAI-1 was mainly found to be expressed in human 
simple columnar epithelial cells of ducts, tubules and 
mucosa1 surface of various organs. HAI-1 was not 
detected in hepatocytes, endocrine cells, stromal 
mesenchymal cells and inflammatory cells (Kataoka et 
al., 1999). 
Patterns of HAI-1 and HAI-2 mRNA have been 
examined. It appears to be that the expression levels 
between HAi-1 and HAI-2 were of similar distribution 
in the tissue examined, except in adult testis, were HAi-2 
expression was far greater than that of HAI-1 
(Kawaguchi et al., 1997). These results suggest that 
HAi-1 and HAI-2 work in unison to specificaily inhibit 
HGFA action. 
Patterns of expression 
There appears to be an inverse correlation between 
tumour progression and HAi-1 mRNA expression. HAI- 
1 was expressed in the normal colorectal mucosa, 
although the degree of expression appeared to be 
decreased in adenocarcinoma tissues of the colorectum. 
Also, it was noted that the carcinoma cell lines 
expressing HAi-1 did not express any detectable level of 
HGFA mRNA (Kataoka et al., 1998). 
The liver hepatocytes, a rich source of HGFA 
mRNA, normally show little or no signal for HAI-1 
mRNA. However, during hepatitis the scattered 
hepatocytes did reveal the presence of HAI-1. Also, an 
enhanced expression of HAi-1 was also observed during 
regeneration of kidney tubule epithelial cells following 
infarction (Kataoka et al., 1999). 
alpha-chain 
lmplications in cancer 
Evidence suggests that the expression of HAI-1 
mRNA in colon carcinoma tissues is down regulated 
(Kataoka et al., 1998), this would aid tumour 
progression as a decreased level of HAI-1 would limit 
the suppression effect on HGFA. Therefore, HGFA 
activity increases resulting in increased conversion of 
pro-HGF to HGFISF, thus leading to tumour cell 
migration and invasion. 
The fact that HGFISF plays such a key role in cancer 
metastasis, suggests that the serine protease HGFA and 
its inhibitors HAI-1 and HAI-2 are important factors 
influencing tumour cell progression. The balance 
between proteases and their inhibitors has been 
implicated as mediating the progression of tumour cells 
(Declerk and Imren, 1994). Furthermore, the balance 
between proteolytic activation and inhibition on a cells 
surface is reported as being disrupted in cancer cells 
(Takada et al., 1995). 
It has been shown that HAI-1 expression is down 
regulated in adenocarcinoma tissues of the colorectum 
(Kataoka et al., 1998), whereas, overexpression of 
HGFA was observed in breast cancer (Hiscox et al., 
1998), these situations results in enhanced tumour 
metastasis. 
Contrary to this, the novel kunitz-type protease 
inhibitor known as KOP was overexpressed in pancreatic 
cancer cells. KOP has been recognised as a gene 
homolog to bikunin, which was suggested to be identical 
to HAI-2. However, it is uncertain what is KOP7s target 
protease for inhibition, and whether KOP has the ability 
to inhibit HGFA (Muller-Pillasch et al., 1998). 
HAi-1 and HAi-2 could act to inhibit HGFA action 
concomrnittantly, or they may be needed to function in 
different situations and be expressed in different tissues. 
Shimomura et al., (1999), revealed that the new soluble 
forms of HAI-1 have different inhibitor action against 
HGFA. Although, the underlying mechanisms behind 
Uature HGFlSP Flg. 3. Stnicture of mature human HGFISF and NK4. 
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this are not known at the present. Further examination of 
HAI-1, HAI-2 and HGFA interaction in the various 
tissues is required to discover if the down-regulation of 
HAi-112 andlor over expression of HGFA is a possible 
prognostic factor in cancer metastasis. Also, the specific 
proteolytic cleavage required to release a form of HAI-1 
should be further investigated, as this processing by a 
specific protease plays a key role in the control of HAI-1 
activity. 
At the present time the role of HAI-1 and HAi-2 in 
tumours is uncertain. However, it appears that the cell 
expression and localisation of HAI-1 mediates tissue 
injury and regeneration, through interaction with HGFA. 
Other roles for HA/- 1 and HA/-2 
Kunitz domain 1 in HAI-1 and 2 is responsible for 
the inhibition of HGFA action, however the role of the 
kunitz domain 2 is unknown, maybe HAI-112 play 
another inhibitory role for another serine protease such 
as trypsin, plasmin or kallikrein as HAI-2 has been 
reported as being identical to KOP and Bikunin. 
Although Kawaguchi et al., (1997), did report that 
the proteolytic processing of HAI-2 appeared to occur in 
the kunitz domain 2. Therefore, the proteolytic cleavage 
of HAI-2 will have to be further characterised to 
understand the function of the kunitz domain 2. 
HGFISF antagonists 
Mature HGFISF, after conversion by HGFA, is 
composed of an a- and B-chain, which are disulphide- 
linked. The mature form is processed from a single chain 
pro-HGFISF (Fig. 3) (Nakamura et al., 1989). The a- 
chain of mature HGFISF contains some of the most 
interesting features of this cytokine, as the N-terminus is 
composed of a hair-pin domain and four homologous 
kringle domains, while the C-terminus of the a-chain is 
linked to the B-chain. The hair-pin and the first two 
kringles are known to be essential for receptor binding. 
Fig. 4. The effect of NK4 on HGFlSF induced 
angiogenesis (Jiang et al., 1999). NK4 was able to 
antagonize in vitro tubule formation induced by 
HGFISF, from hurnan vascular endothelial cells. 
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Interaction between the receptor and the binding domain 
stimulates the kinase domain of cMET, which further 
activates downstream events. 
The striking effect of HGFISF on cancer cells, the 
established relationship between the cytokine and its 
receptor, and disease progression and prognosis of breast 
cancer bearing patients, has prompted attempts to 
minimise the effect of HGFISF in vitro and in vivo. The 
possibility of using part of HGFISF as antagonists to 
HGFISF through competitive binding to cMET has been 
postulated. The extensively tested strategy involved 
using the receptor-binding domain of the a-chain. 
Alternative spliced variants of the a-chain, which 
contain different parts of the subunit have been 
discovered previously. The variant that contains the hair- 
pin and the first kringle domain (Kl), is known as 
HGFINKl and is naturally occurring. The one that 
contains the hair-pin and the first and the second kringle 
domains ( m ) ,  is known as HGF/NK2. Both variants are 
able to bind to the receptor and have been shown to act 
as partial agonists and partial antagonists (Chan et al., 
1991; Hartman et al., 1992; Lokker and Godowski 1993; 
Cioce et al., 1996; Schwall et al., 1996). For example, 
NK2 has no mitogenic effect on hepatocytes, but retains 
motogenic and pro-metastasis effect (Otsuka et al., 
2000). Both variants have no therapeutic value in term of 
cancer intervention, due to their induction of cancer 
motility, while the B-chain has no receptor binding 
capacity and does not elicit any HGFISF effects. 
Recently, a further breakthrough has been achieved 
in this aspect of HGFISF and antagonistic variant. A 
protein that contains the hair-pin and al1 four kringle 
domains has been obtained, and so named NK4 (Date et 
al., 1997). NK4 has exhibited a completely different 
biological spectrum, as opposed to that of NK1 and 
NK2. NK4 is generated through enzymatic cleavage of 
mature human HGFJSF, whose receptor binding hair-pin 
and the four kringle domains have been retained, but the 
B-chain and amino acids which are responsible for 
dimerisation on the C-terminus of a-chain (Fig. 3), have 
been removed. The new variant is a protein of 50 kDa in 
size. NK4 thus has retained a receptor-binding domain, 
but has the following properties that were previously 
unknown: i. NK4 is able to specifically bind to HGFISF 
receptor; ii. NK4 is unable to activate HGFISF receptor, 
but able to compete with HGFISF in the receptor 
binding, thus deactivate HGFISF induced receptor 
activation in MDCK cells; iii. NK4 has no mitogenic 
effect and abolishes the mitogenic effect induced by 
HGFISF in hepatocytes; iv. NK4 has no motogenic effect 
and abolishes the motogenic effects of HGFISF on 
MDCK cells; and finally NK4 has no morphogenic 
effect and diminishes the morphogenic effects induced 
by HGFISF on MDCK cells. The initial study thus 
indicates NK4 as being a complete antagonist of 
HGFJSF in the hepatocytes and MDCK cells (Date et al., 
1997; Matsumoto et al., 1998). For example, NK4 was 
able to inhibit the in vitro angiogenesis without eliciting 
an agonistic activity on the process (Fig. 4) (Jiang et al., 
1999b). NK4 also inhibited the migration, and in vitro 
invasion of breast, colon and bladder cancer cells (Fig. 
5) (Hiscox et al., 2000; Parr et al., 2000). Interestingly, 
delivery of NK4 transcript by means of adenovirus has 
also been shown to exert strong anti-cancer effects 
(Maekaedo et al., 2000). Thus, this specific HGFISF 
antagonist may offer a unique and strong opportunities 
for the treatment of cancer, associated with abnormal 
expression of HGFISF andlor its receptor. 
Flg. 5. EWects of NK4 on HGFBF induced A l  rnotili (lefi) and its receptor (MET) activation (right) (Parr et al 2000). Left: A: colon cancer ceils without 
HQFISF; B: cells wRh human HGFBF; C: a combination of HGFISF and NK4; and D: cells with NK4 alone. RlgM: The effects of NK4 on the HGFISF 
receptor. HT115 h u m  d o n  oanw cells were Baated as indicated. Pfiorsphotylated HGFBF receptor was detected with immunoprecipitatlon and 
Westem W n g .  NK4 enippreased HGFBF-induced receptor activation. 
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Non-specific inhibitors to HGFISF 
Interestingly EGF inhibits HGF-induced migration 
in the gastric cancer cell line, MKN7, possibly by 
regulating the phosphorylation status of c-met in these 
cells (Takeuchi, 1996). 
Polyunsaturated fatty acids 
Gamma linolenic acid (GLA) is an n-6 essential fatty 
acid which has been shown to cytotoxic towards tumours 
both in vitro and in vivo (Begin et al., 1986; Horrobin, 
1990; Jiang et al., 1996c, 1998). We have shown that 
GLA exerts a potent inhibitory effect on HGFISF- 
stimulated tumour cell motility, invasion, and membrane 
ruffling at concentrations that are non-toxic to the cells 
(Jiang et al., 1995a, 1996b), possibly by the regulation of 
the cell-surface adhesion molecule, E-cadherin (Jiang et 
al., 1995b,c). Interestingly, GLA also inhibits the 
adhesion of tumour cells to extracellular matrix via 
inhibition of FAK and paxillin phosphorylation (Jiang et 
al. ,  1996d). A link between such an effect and 
peroxisome proliferator activated receptor (PPAR) has 
been recently proposed (Jiang et al., 2000). This may 
represent a further mechanism by which GLA inhibits 
HGFISF-induced cell motility. 
IL-4 and IL- 12 
IL-4 has been found to be able to inhibit HGFISF- 
induced motility and invasion of colorectal cancer cells 
(Uchiyama et al., 1996). IL-12 is  a monocytel 
lymphocyte derived cytokine which has a strong effect 
on NK cells and cytotoxic T lymphocytes and may thus 
represent an important anti-cancer cytokine (Hiscox and 
Jiang, 1997~).  We have also shown that this immuno- 
regulatory cytokine, inhibits tumour cell motility and 
basement membrane invasion stimulated by HGFISF 
(Hiscox et al., 1995). These effects are thought to be 
mediated by alterations in cell-surface adhesion 
molecule levels. 
lnvasion inhibitory factor-2 
Invasion inhibiting factors are small proteins 
extracted from the liver which exhibit anti-metastatic 
properties in melanoma and lung cancer cells in vivo 
(Isoai et al., 1992, 1993). Invasion inhibitory factor-2 
(IIF-2) (Isoai et al., 1992, 1993, 1994), has been shown 
to inhibit HGFISF-stimulated motility and invasion of 
tumour cells in vitro (Jiang et al., 1995d; Han et al., 
1996) however the mechanism by which this occurs is 
not clear. 
Retinoic acid 
Retinoic acid, which belongs to a group of vitamin A 
metabolites, has been shown to exert opposite effects on 
the same cell (Koj et al., 1995), including regulation of 
cytokine production and acute phase responses at a 
transcription level. Retinoic acid has been widely 
reported to be involved in the regulation of other motility 
factor receptor functions, cell-matrix interactions and 
proteolytic enzymes (Edward et al., 1989; Hendrix et al., 
1990; Lotan et al., 1992). 
Cell adhesion molecule-mediated inhibition of the effects 
of HGF/SF 
It has been reported that restoring the function of or 
raising the leve1 of E-cadherin inhibits HGFJSF-induced 
cancer cell invasion (Jiang et al., 1995c; Jiang, 1996). 
Restoring E-cadherin mediated cell-cell adhesion by 
T iaml  or RacV12 gene transfection also reduces 
HGFJSF induced cell scattering (Hordijk et al., 1997). 
HGFISF also enhances the phosphorylational status of B- 
catenin, a possible mechanism surrounding the HGFISF- 
induced scattering of epithelial cells. Clearly, further 
investigations concerning the interplay between HGFISF 
and cell-cell  adhesion complexes such as  the E- 
cadherinlcatenin complex may present further ways of 
inhibiting the metastatic-promoting effects of HGFISF. 
Modulation of intracellular Ca2+ 
HGFJSF-induced tumour cell membrane ruffling and 
motility have been shown to be inhibited by the addition 
of cytosolic calcium regulating agents such as ATP 
(Jiang et al., 1995a). Transient elevation of intracellular 
c a 2 +  levels is thought play a role in the HGFISF- 
inhibitory mechanism of ATP as inhibition of this ca2+ 
raise by BAPTA abolishes the inhibitory effects of ATP. 
Elevation of cytosolic free ca2+  with other agents 
including ionomycin and ADP also results in HGFISF 
inhibition. 
Recent new approaches 
c-MET inhibitors 
Although c-MET is a prime target for intervention, 
specific inhibitors to c-MET has not been described until 
recently. Lipson and colleagues have recently reported to 
have discovered selective pyrroleindolinone c-MET 
kinase inhibitors (Lipson et al., 2000). In a brief report, it 
revealed that these inhibitors can inhibit HGFISF 
induced c-MET phosphorylation and cellular response, 
including cell migration and invasion. This may offer a 
new direction in the inhibition of HGFJSF activity. 
However, in vivo testing are required for this in order to 
evaluate the effectiveness and toxicity of these 
compounds. 
Antisense-hammerhead ribozyme approach to target 
HGF/SF and/or c-MET 
The antisense approach to suppress the expression of 
specific mRNA has been in testing for some time, with 
HGF/SF inhibitors in cancer 
limited success. However, a recent study using a small 
hammerhead ribozyme (a small RNA) to target HGFISF 
and c-MET has yield some very interesting results. 
Abounader and Laterra (1999), have constructed short 
antisense sequences of HGFISF and c-MET to a 
hammerhead ribozyme. The recognition of the specific 
sequence by the ribozyme result in the generation of 
anti-sense oligonuceotides. These ribozyme constructs 
were subsequently cloned into a bacteria1 vector. The 
authors use these plasmids to generate a stable tumour 
transfectant, which carry these construct. The authors 
elegantly showed that cells carrying these hammerhead 
construct constantly produce specific antisense oligos to 
either HGFISF or c-MET mRNA and result in the 
destruction of these molecules. These transfectants 
exhibited far lower tumourigenecity and low capacity in 
tumour progression, compared with the wild type. 
Anisamycin antibiotics 
Recently, it has been reported that certain members 
of the geldanamycin family of anisamycin antibiotics are 
potent inhibitors of HGFISF-mediated plasmin 
activation, displaying inhibitory properties at femtomolar 
concentrations and nine orders of magnitude below their 
growth inhibitory concentrations. These antibiotics were 
initially discovered as inhibitors of the src family of 
tyrosine kinases (Uehara et al., 1988; Whitesell et al., 
1994; Roe et al., 1999). At nanomolar concentrations, 
the geldanamycins down-regulate c-Met protein 
expression, inhibit HGFISF-mediated cell motility and 
invasion, and also revert the phenotype of both autocrine 
HGFISF-c-Met transformed cells as well as those 
transformed by c-Met proteins with activating mutations 
(Webb et al., 2000). 
Conclusions 
The past decade has seen the rapid expansion of the 
knowledge on the role of HGFISF and its receptor in 
cancer. The factor is now known to widely involved in 
cellular migration, matrix adhesion and degradation, and 
invasiveness of cancer cells. It is  also a potent 
angiogenic factor. Clinical studies have demonstrated a 
clear inverse relationship between the factorlreceptor and 
progression and prognosis of patients with cancer. 
Recent efforts to identify the activation pathways of the 
factor and importantly, inhibitors and antagonists, have 
presented some new opportunities in combating this 
factor in settings, such as cancer. Although most of the 
inhibitors are still at a development stage, further 
progress will undoubtedly lead to applying some of these 
technologies to the therapy of cancer, particularly those 
associated with a high HGFISF andlor high c-MET 
conditions. 
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